Inhibition of tumor necrosis factor-α with anti-diabetic agents
- 1 March 1999
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 43 (3) , 147-154
- https://doi.org/10.1016/s0168-8227(99)00005-4
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.Journal of Clinical Investigation, 1998
- The expression of TNF alpha by human muscle. Relationship to insulin resistance.Journal of Clinical Investigation, 1996
- Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors.Journal of Clinical Investigation, 1994
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993
- Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB ratsClinical Immunology and Immunopathology, 1992
- Gliclazide: a general free radical scavengerEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: A comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocinThe American Journal of Medicine, 1991
- Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice.Journal of Clinical Investigation, 1989
- The Relationship Between the Pharmacokinetics and Pharmacodynamic Effects of Oral Hypoglycaemic DrugsClinical Pharmacokinetics, 1987
- GliclazideDrugs, 1984